Exercise and Pioglitazone for HIV-Metabolic Syndromes
The clinical trial investigated the combined effects of pioglitazone, a PPAR-gamma agonist, and structured exercise training on metabolic syndromes in HIV-infected individuals. Given the rising prevalence of metabolic disorders among HIV patients, this study addresses a significant unmet medical need. The findings could enhance pioglitazone's market positioning against other diabetes and metabolic syndrome treatments, particularly in the context of HIV-associated complications. The results may also support the development of combination therapies, potentially leading to new indications for pioglitazone and exercise interventions in this patient population.
Indication: HIV Infections
Modality: small molecule
Target: PPAR-gamma (Peroxisome Proliferator-Activated Receptor gamma) and PPAR-alpha
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PPAR-gamma (Peroxisome Proliferator-Activated Receptor gamma) and PPAR-alpha
View original source fields
Condition raw: HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Condition normalized: HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PPAR-gamma (Peroxisome Proliferator-Activated Receptor gamma) and PPAR-alpha
Target normalized: PPAR-gamma (Peroxisome Proliferator-Activated Receptor gamma) and PPAR-alpha